|
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Clinical research trials and Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma. Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma clinical trial. Human subjects often get the best healthcare possible for their Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma  Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
For Condition: perioperative/postoperative complications,localized malignant mesothelioma,Quality of Life,advanced malignant mesothelioma
Status: Recruiting
Sponsor(s): Cancer Research UK Clinical Trials Unit at the University of Glasgow ,
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if radiation therapy is effective in preventing metastatic cancer following surgery. PURPOSE: Randomizedphase III trial to determine the effectiveness of radiation therapy in preventing metastatic cancer in patients who have undergone diagnostic procedures to identify malignant mesothelioma.
Details: OBJECTIVES: - Determine the efficacy of radiotherapy in the prevention of metastatic skin nodules or tumor seeding following invasive diagnostic procedures, such as chest drain insertion, pleural aspiration, pleural biopsy, and thoracoscopy, in patients with malignant mesothelioma. - Determine whether the nodules that develop after radiotherapy are symptomatic in these patients. - Compare the quality of life of patients treated with radiotherapy vs standard care alone. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive radiotherapy on 3 consecutive days beginning within 3 weeks after chest drain insertion, pleural aspiration, pleural biopsy, or thoracoscopy and once the wounds have healed. - Arm II: Patients receive standard supportive care alone. Quality of life is assessed at baseline, and then at 1, 2, 4, 6, 9, and 12 months. Patients are followed at 1, 2, 4, 6, 9, and 12 months. PROJECTED ACCRUAL: A total of 44 patients (22 per arm) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven malignant pleural mesothelioma by chest drain insertion, pleural aspiration, pleural biopsy, and/or thoracoscopy within the past 3 weeks PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Not specified Life expectancy: - At least 3 months Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior systemic chemotherapy for malignant mesothelioma Endocrine therapy: - Not specified Radiotherapy: - No prior local radiotherapy for malignant mesothelioma Surgery: - See Disease Characteristics - No other invasive procedures to the same chest site during and for 1 year after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
NoelleO'Rourke, Study Chair, University of Glasgow
Stobhill General Hospital *Recruiting*
Glasgow, Scotland, G21 3UW
United Kingdom
Recruiting R Jones 44-141-201-3000
Gartnavel General Hospital *Recruiting*
Glasgow, Scotland, G12 0YN
United Kingdom
Recruiting Andrew Peacock 44-141-211-3000
Beatson Oncology Centre *Recruiting*
Glasgow, Scotland, G11 6NT
United Kingdom
Recruiting Noelle O'Rourke 0414-211-1738
Additional Information:
Study ID Numbers: CDR0000068155; CRC-BOC-L52,EU-20033
Study Start Date:
Record last reviewed: September 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006231
Other Advanced Malignant Mesothelioma Studies:
1. Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
2. Cisplatin With or Without LY231514 in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
3. Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
4. Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
5. Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
Related Studies:
Other advanced malignant mesothelioma Clinical Trials
Other Scotland Clinical Trials
Other Glasgow Clinical Trials
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
|
|
|
|
|
|
|
|
